(Source: GSK - GlaxoSmithKline plc) 32 week maintenance data presented at CROI showed comparable viral suppression rates between injectable regimen and three drug oral regimen Issued: London London, UK, 23 February 2016 - ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today presented positive results from the LATTE-2 study at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. Headline results were announced in November 2015. LATTE-2 is a phase IIb, open label study investigating the long-acting, injectable formulations of cabotegravir (ViiV Healthcare) and rilpivirine (Janssen...
↧